12Jun 2023
Enoxaparin As Effective As Aspirin For Lowering Symptomatic VTE Risk After Arthroplasty

Enoxaparin As Effective As Aspirin For Lowering Symptomatic VTE Risk After Arthroplasty

A secondary analysis of a cluster randomized crossover clinical trial by The CRISTAL Study Group discovered no difference in mortality after 90 days between patients assigned to enoxaparin versus aspirin for venous thromboembolism (VTE) prevention. Following these operations, aspirin has been postulated as a medication that might lower mortality as venous thromboembolism prophylaxis due to its antiplatelet and cardioprotective effects. Twenty-three thousand four hundred fifty-eight patients from 31 institutions were involved, with 14 156 assigned to aspirin and 9302 assigned to enoxaparin. Within 90 days of surgery, the aspirin group had a death rate of 1.67%, while the enoxaparin group had a mortality rate of 1.53%. The death rate in the 21 148 patients with a non-fracture diagnosis subgroup was 0.49% in the aspirin group and 0.41% in the enoxaparin group.

  • #rheumatology

Like

Save

Share